Latest Breaking News On - 023 prnewswire venus medtech is changing how the world treats structural heart disease company will present its products at booth 28 - Page 1 : comparemela.com

The company will be presenting its growing pipeline of superb technologies for treating all four heart valves in its booth and at multiple events during the conference. HANGZHOU, China, Nov. 20, 2023 /PRNewswire/ Venus Medtech is changing how the world treats structural heart disease. The company will present its products at its booth (#28), during two symposia, in multiple podium presentations and at a special cocktail reception where it will officially launch the SMART-ALIGN multicenter clinical study. Structural heart symposia on November 20 and 21 The company will be hosting two symposia on November 20 and 21 that will allow interventional cardiologists to deepen their knowledge about structural heart interventions. The first, "Valve tricuspid Transcatheter: Cardiovalve keeps it in motion" will be dedicated to discussing the latest results and future plans for the Cardiovalve tricuspid valve replacement system. In the second, "Addressing remaining issues after TAVI

City ofUnited kingdomPrnewswire venus medtechVenus medtechVenus vitae transcatheter heart valve systemLondon valvesThe company will be presenting its growing pipeline of superb technologies for treating all four heart valves in booth and at multiple events during conference hangzhouNov 20023 prnewswire venus medtech is changing how the world treats structural heart disease company will present its products at booth 28Uring two symposiaN multiple podium presentations and ata special cocktail reception where it will officially launch the smart align multicenter clinical study structural heart symposia on november 20 21 company be hosting two that allow interventional cardiologists to deepen their knowledge about interventions firstUot valve tricuspid transcatheter cardiovalve keeps it in motion quot will be dedicated to discussing the latest results and future plans for replacement system secondUot addressing remaining issues after tavi what to expect from the new generationUot presenters will focus on the tools and techniques showcasing venus vitae launching smart align study with registration studies commencing annually additionallyEnus will be officially launching the smart align study to evaluate performance of venus vitae transcatheter heart valve system in patients with severe aortic stenosis enroll 150 at 20 medical centers worldwide this new builds on target launched london valves 2022Hich is evaluating the cardiovalve system for transcatheter tricuspid valve replacement now on track ce mark approval in late 2026